Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy

International Journal of Cardiology

Volumn 196, Issue , 2015, Pages 115-122

  Derda, Anselm A ^a   Thum, Sabrina ^a   Lorenzen, Johan M ^a   Bavendiek, Udo ^a   Heineke, Joerg ^a   Keyser, Britta ^a   Stuhrmann, Manfred ^a   Givens, Raymond C ^b   Kennel, Peter J ^b   Christian Schulze, P ^b   Widder, Julian D ^a   Bauersachs, Johann ^a   Thum, Thomas ^a,c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NewYork Presbyterian Hospital   (United States)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Amyloidosis; Aortic stenosis; Biomarker; Diagnosis; Hypertrophic cardiomyopathies; MicroRNA

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 1; MICRORNA 133A; MICRORNA 155; MICRORNA 21; MICRORNA 29A; MICRORNA 29B; MICRORNA 29C; MICRORNA 499; UNCLASSIFIED DRUG; CARDIAC MYOSIN; CARRIER PROTEIN; MIRN29 MICRORNA, HUMAN; MYH7 PROTEIN, HUMAN; MYOSIN HEAVY CHAIN; MYOSIN-BINDING PROTEIN C;

ADULT; AGED; AORTA STENOSIS; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; HEART AMYLOIDOSIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; HYPERTROPHIC NON OBSTRUCTIVE CARDIOMYOPATHY; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MYBPC3 GENE; MYH7 GENE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RNA ANALYSIS; AMYLOIDOSIS; AORTIC VALVE STENOSIS; BLOOD; CARDIOMYOPATHY, HYPERTROPHIC; CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION PROFILING; GENETICS; MIDDLE AGED; MUTATION; PHYSIOLOGY; POLYMERASE CHAIN REACTION;

ADULT; AGED; AMYLOIDOSIS; AORTIC VALVE STENOSIS; BIOMARKERS; CARDIAC MYOSINS; CARDIOMYOPATHY, HYPERTROPHIC; CARRIER PROTEINS; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MUTATION; MYOSIN HEAVY CHAINS; POLYMERASE CHAIN REACTION;

EID: 84937407012     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.05.185     Document Type: Article

References (21)

1. B.J. Maron, and M.S. Maron Hypertrophic cardiomyopathy Lancet 381 9862 2013 242 255 (1/19-25)
2. Authors/Task Force members, P.M. Elliott, A. Anastasakis, and et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC) Eur. Heart J. 35 39 Oct. 14 2014 2733 2779
3. L. Song, M. Su, S. Wang, and et al. MiR-451 is decreased in hypertrophic cardiomyopathy and regulates autophagy by targeting TSC1 J. Cell. Mol. Med. 18 11 Nov. 2014 2266 2274
4. R. Roncarati, C. Viviani Anselmi, M.A. Losi, and et al. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy J. Am. Coll. Cardiol. 63 9 Mar. 11 2014 920 927
5. T. Thum, C. Gross, J. Fiedler, and et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts Nature 456 7224 Dec. 18 2008 980 984
6. A. Care, D. Catalucci, F. Felicetti, and et al. MicroRNA-133 controls cardiac hypertrophy Nat. Med. 13 5 May 2007 613 618
7. E. van Rooij, and E.N. Olson MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles Nat. Rev. Drug Discov. 11 11 Nov. 2012 860 872
8. T. Thum Noncoding RNAs and myocardial fibrosis Nat. Rev. Cardiol. 11 11 Nov. 2014 655 663
9. M. Jaguszewski, J. Osipova, J.R. Ghadri, and et al. A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction Eur. Heart J. 35 15 Apr. 2014 999 1006
10. C. Bauters, R. Kumarswamy, A. Holzmann, and et al. Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction Int. J. Cardiol. 168 3 Oct. 3 2013 1837 1840
11. R. Kumarswamy, and T. Thum Non-coding RNAs in cardiac remodeling and heart failure Circ. Res. 113 6 Aug. 30 2013 676 689
12. C. Widera, S.K. Gupta, J.M. Lorenzen, and et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome J. Mol. Cell. Cardiol. 51 5 Nov. 2011 872 875
13. R. Kumarswamy, A.R. Lyon, I. Volkmann, and et al. SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway Eur. Heart J. 33 9 May 2012 1067 1075
14. Y. Zhang, X.R. Huang, L.H. Wei, A.C. Chung, C.M. Yu, and H.Y. Lan miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-beta/Smad3 signaling Mol. Ther. 22 5 May 2014 974 985
15. J.P. Duong Van Huyen, M. Tible, A. Gay, and et al. MicroRNAs as non-invasive biomarkers of heart transplant rejection Eur. Heart J. 35 45 Dec. 1 2014 3194 3202
16. T.S. Elton, H. Selemon, S.M. Elton, and N.L. Parinandi Regulation of the MIR155 host gene in physiological and pathological processes Gene 532 1 Dec. 10 2013 1 12
17. H.Y. Seok, J. Chen, M. Kataoka, and et al. Loss of MicroRNA-155 protects the heart from pathological cardiac hypertrophy Circ. Res. 114 10 May 9 2014 1585 1595
18. W.Y. Lew, E. Bayna, E. Dalle Molle, R. Contu, G. Condorelli, and T. Tang Myocardial Fibrosis Induced by Exposure to Subclinical Lipopolysaccharide Is Associated with Decreased miR-29c and Enhanced NOX2 Expression in Mice PLoS One 9 9 Sep. 18 2014 e107556
19. T. Nguyen, C. Kuo, M.B. Nicholl, and et al. Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma Epigenetics 6 3 Mar. 2011 388 394
20. M. Palacin, J.R. Reguero, M. Martin, and et al. Profile of microRNAs differentially produced in hearts from patients with hypertrophic cardiomyopathy and sarcomeric mutations Clin. Chem. 57 11 Nov. 2011 1614 1616
21. S. Batkai, and T. Thum Analytical approaches in microRNA therapeutics J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 964 Aug. 1 2014 146 152